Curis (NASDAQ:CRIS) Coverage Initiated at StockNews.com

Research analysts at StockNews.com started coverage on shares of Curis (NASDAQ:CRIS) in a research report issued on Monday. The brokerage set a “hold” rating on the biotechnology company’s stock.

Separately, HC Wainwright dropped their price target on Curis from $20.00 to $16.00 and set a “buy” rating for the company in a report on Monday, March 31st.

Curis Price Performance

NASDAQ CRIS opened at $1.29 on Monday. Curis has a twelve month low of $1.02 and a twelve month high of $16.99. The stock has a market cap of $10.95 million, a P/E ratio of -0.17 and a beta of 3.51. The company’s 50-day simple moving average is $2.46 and its 200 day simple moving average is $3.49.

Curis (NASDAQ:CRIS) last released its quarterly earnings data on Monday, March 31st. The biotechnology company reported ($1.25) earnings per share for the quarter, beating the consensus estimate of ($1.36) by $0.11. The company had revenue of $2.70 million for the quarter, compared to analyst estimates of $2.04 million. Curis had a negative return on equity of 923.37% and a negative net margin of 443.35%. Research analysts anticipate that Curis will post -7.12 earnings per share for the current year.

Hedge Funds Weigh In On Curis

Several hedge funds have recently added to or reduced their stakes in CRIS. Focused Wealth Management Inc lifted its holdings in Curis by 9.5% during the fourth quarter. Focused Wealth Management Inc now owns 59,204 shares of the biotechnology company’s stock worth $181,000 after acquiring an additional 5,138 shares in the last quarter. CM Management LLC boosted its position in Curis by 83.3% during the fourth quarter. CM Management LLC now owns 220,000 shares of the biotechnology company’s stock valued at $673,000 after purchasing an additional 100,000 shares during the last quarter. Geode Capital Management LLC grew its stake in shares of Curis by 27.3% in the fourth quarter. Geode Capital Management LLC now owns 83,129 shares of the biotechnology company’s stock valued at $254,000 after buying an additional 17,820 shares in the last quarter. M28 Capital Management LP grew its position in shares of Curis by 23.5% in the 4th quarter. M28 Capital Management LP now owns 521,059 shares of the biotechnology company’s stock valued at $1,594,000 after acquiring an additional 99,108 shares during the period. Finally, Samsara BioCapital LLC acquired a new position in Curis during the fourth quarter worth approximately $607,000. Institutional investors and hedge funds own 29.97% of the company’s stock.

Curis Company Profile

Curis, Inc, a biotechnology company, engages in the discovery and development of drug candidates for the treatment of human cancers in the United States. Its clinical stage drug candidates include Emavusertib, an oral small molecule IRAK4 kinase inhibitor, which is in a Phase 1/2 open-label, single arm expansion trial in patients with relapsed or refractory, or R/R, AML and high-risk myelodysplastic syndromes.